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Background
Malignant Hyperthermia is a life-threatening condition
triggered by exposure to certain general anaesthetics
(halothane, sevoflurane, and desflurane) and depolarising
muscle relaxants (suxamethonium). Malignant hyperther-
mia happens primarily due to mutation of the ryanodine
receptor type 1 (RYR1), located on the sarcoplasmic reticu-
lum in myocytes. This mutation leads to increase in cal-
cium release, muscle contraction, and heat production.
Dantrolene, a skeletal muscle relaxant, is the drug of choice
for malignant hyperthermia because it binds to RYR1 and
thereby reduces the calcium released from the sarcoplasmic
reticulum.[1] Dantrolene has been shown to significantly
reduce mortality when given promptly.[2,3] A hospital is
recommended to keep a minimum stock of 36 dantrolene
vials, which provides 720 mg of dantrolene sufficient for a
70-kg person.[4] This study investigates whether the hospi-
tals in the region of Fraser Health Authority, Canada, have
sufficient dantrolene vials in stock.
Methods
A visit was made to the eleven hospitals’ operating rooms
in the region. The expiry date and location of the dantro-
lene vials were recorded. The operating room staff were
interviewed to determine their knowledge on the treat-
ment procedure of malignant hyperthermia.
Results
Four of the hospitals were found to have less than 36 vials
of dantrolene in the operating rooms. Most of the staff
never treated patients with malignant hyperthermia and
did not know the reconstitution procedure of dantrolene.
Conclusions
A dantrolene cart, which consisted of 36 vials of dantrolene
and a simplified reconstitution instruction, was determined
to be necessary. The cart would also have other supplies
for management of malignant hyperthermia, including fur-
osemide, lidocaine, calcium chloride, dextrose, sodium
bicarbonate, sterile water, regular human insulin, and syr-
inges. Routine stock quantity and expiry date checks would
be carried out. One of the hospitals was recommended to
stock 72 vials of dantrolene. The extra vials would be trans-
ferred to another hospital during shortage of dantrolene in
emergency situations. Quarterly drills on reconstitution of
dantrolene and treatment of malignant hyperthermia were
also deemed to be necessary.
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